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Summary
Background In patients with suspected coronary heart disease, single-photon emission computed tomog raphy 
(SPECT) is the most widely used test for the assessment of myocardial ischaemia, but its diagnostic accuracy is 
reported to be variable and it exposes patients to ionising radiation. The aim of this study was to establish the 
diagnostic accuracy of a multi parametric cardiovascular magnetic resonance (CMR) protocol with x-ray coronary 
angiography as the reference standard, and to compare CMR with SPECT, in patients with suspected coronary 
heart disease.
Methods In this prospective trial patients with suspected angina pectoris and at least one cardiovascular risk factor 
were scheduled for CMR, SPECT, and invasive x-ray coronary angiography. CMR consisted of rest and adenosine 
stress perfusion, cine imaging, late gadolinium enhancement, and MR coronary angiography. Gated adenosine stress 
and rest SPECT used ⁹⁹mTc tetrofosmin. The primary outcome was diagnostic accuracy of CMR. This trial is registered 
at controlled-trials.com, number ISRCTN77246133.
Findings In the 752 recruited patients, 39% had signiﬁ cant CHD as identiﬁ ed by x-ray angiography. For multiparametric 
CMR the sensitivity was 86·5% (95% CI 81·8–90·1), speciﬁ city 83·4% (79·5–86·7), positive predictive value 77·2%, 
(72·1–81·6) and negative predictive value 90·5% (87·1–93·0). The sensitivity of SPECT was 66·5% (95% CI 
60·4–72·1), speciﬁ city 82·6% (78·5–86·1), positive predictive value 71·4% (65·3–76·9), and negative predictive value 
79·1% (74·8–82·8). The sensitivity and negative predictive value of CMR and SPECT diﬀ ered signiﬁ cantly (p<0·0001 
for both) but speciﬁ city and positive predictive value did not (p=0·916 and p=0·061, respectively). 
Interpretation CE-MARC is the largest, prospective, real world evaluation of CMR and has established CMR’s high 
diagnostic accuracy in coronary heart disease and CMR’s superiority over SPECT. It should be adopted more widely 
than at present for the investigation of coronary heart disease. 
Funding British Heart Foundation.
Introduction
Coronary heart disease is a leading cause of death and 
disability.1 Various techniques are used to diagnose 
coronary heart disease and assess the need for 
revascularisation. Increasingly, imaging tests have 
replaced exercise treadmill testing, with single-photon 
emission computed tomography (SPECT) being the most 
common. However, although a negative SPECT result 
provides reassuring prognostic information, it exposes 
patients to ionising radiation, and estimates of its 
accuracy vary widely.2–4
Cardiovascular magnetic resonance (CMR) imaging 
could be an alternative to SPECT. Theoretical advantages 
of CMR include the lack of ionising radiation, high 
spatial resolution, and its multiparametric nature—ie, 
its ability to assess multiple aspects of pathology in a 
single examination (eg, ventricular function, myocardial 
perfusion, viability, and coronary artery anatomy).5–10 Small 
single7,11–15 and multi centre16,17 studies have tested the 
accuracy of stress-perfusion CMR alone for the detection 
of coronary heart disease and some studies showed equal12 
or improved15 results compared with SPECT. Stress-
perfusion CMR and SPECT performed equally well in a 
subanalysis of a multicentre study (MR-IMPACT).18 
However, this study was underpowered and the population 
was highly selected (the entry criteria were previous 
coronary angiography or a positive SPECT). Evidence 
from large, prospective studies comparing the two 
techniques is lacking. Additionally, multiparametric CMR 
protocols might increase the diagnostic yield compared 
with stress perfusion alone,9 but no large studies have 
investigated their clinical role. The inclusion of coronary 
MR angiography is especially relevant, because this 
component is time-consuming and the image quality is 
more variable than that of other CMR methods.
The Clinical Evaluation of MAgnetic Resonance 
imaging in Coronary heart disease (CE-MARC) study 
was designed to establish the diagnostic accuracy of 
multiparametric CMR in a large real world population, 
and to test the hypothesis that CMR yields higher 
diagnostic performance than SPECT, using X-ray 
angiography as the reference standard.
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Methods
Patients and study design
The methods used in CE-MARC have been published 
previously.19 Patients were recruited between March, 2006, 
and August, 2009, from two hospitals (Pinderﬁ elds 
General Hospital and Leeds Teaching Hospitals NHS 
Trust, UK). Consecutive patients with suspected angina 
pectoris were screened and enrolled if they had at least 
one major cardiovascular risk factor and a cardiologist 
judged them to have stable angina needing investigation, 
in accordance with contemporary clinical practice. 
Exclusion criteria19 were previous coronary artery bypass 
surgery; crescendo angina or acute coronary syndrome; 
contraindication to CMR (eg, pacemaker) or adenosine 
infusion (eg, reversible airways disease, atrioventricular 
block); pregnancy; inability to lie supine; and a glomerular 
ﬁ ltration rate of 30 ml/min per 1·73m² or less. The 
estimated prevalence of clinically signiﬁ cant coronary 
disease was 40–60%.19 Patients were included in the 
primary outcome analysis if they had complete data from 
both CMR and x-ray angiography and had had no interim 
cardiovascular events. The study was done in accordance 
with the Declaration of Helsinki and approved by the local 
research ethics committee. Patients provided informed 
written consent.
Randomisation and masking
Patients were randomly assigned with respect to the order 
they received CMR and SPECT by a 24 h automated 
randomisation service with stratiﬁ ed permuted blocks to 
ensure that the groups were balanced for age (<65 years 
and ≥65 years) and sex. The SPECT, CMR, and x-ray angio-
gram results were analysed in accordance with inter-
national criteria,20–22 by masked, paired readers with at least 
10 years of experience of using their modalities. After x-ray 
angiography, the SPECT result could be made available on 
request to enable a decision about re vascularisation (to 
mask the treating clinician to the result was deemed 
unethical); however, CMR results were kept masked.
Procedures
By protocol all patients were scheduled for x-ray coronary 
angiography. Figure 1 shows the CMR protocol. CMR 
was done at Leeds General Inﬁ rmary with 1·5 Tesla 
Philips Intera CV scanner (Philips Healthcare, Best, 
Netherlands). Panel 1 shows the CMR method, with the 
criteria for positive CMR19 shown in panel 2. 
SPECT radionuclide imaging was done at Leeds 
General Inﬁ rmary with a cardiac gamma camera 
(MEDISO Cardio-C, Budapest, Hungary). Patients 
underwent a standard 2-day protocol with ⁹⁹mTc tetro-
fosmin (Myoview) at a dose of 400 MBq adjusted by 
weight to a maximum 600 MBq per examination (eﬀ ective 
dose 6–9 mSv) as is advised in guidelines.24,25 Stress and 
rest electrocardiogram gated SPECT images were 
acquired with an intravenous adenosine protocol identical 
to that used in CMR (140 μg/kg per min for 4 min) so 
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Figure 1: Cardiovascular magnetic resonance protocol
After a low-resolution survey scan and localisers to deﬁ ne the cardiac long and short axes, intravenous adenosine 
was administered for 4 min at 140 μg/kg per min, during which ﬁ rst-pass stress perfusion imaging was undertaken 
with 0·05 mmol/kg dimeglumine gadopentetate. 3D whole heart MR coronary angiography was done after the 
low resolution coronary survey and free-breathing four chamber cine (used to assess slice coverage and diastolic 
coronary rest period, respectively). Rest perfusion imaging was undertaken a minimum of 15 min after stress 
perfusion, with a further injection of 0·05 mmol/kg dimeglumine gadopentetate. A ﬁ nal injection of 0·1 mmol/kg 
dimeglumine gadopentetate was given after this sequence, bringing the overall gadolinium dose to 0·2 mmol/kg. 
Resting left ventricular function was then assessed, initially for three slices, planned identically to the perfusion 
slices, and then for the entire left ventricle with contiguous slices. A modiﬁ ed Look-Locker inversion time scout 
was done before late gadolinium enhancement imaging in short axis, vertical long axis, and horizontal long axis 
orientations. Times indicated are approximate and sequence blocks are not drawn to scale.
Panel 1: Cardiovascular magnetic resonance imaging parameters
Balanced steady-state free precession cine imaging
10–12 short axis slices (10 mm thick, no gap) with one slice per breath-hold, 1·6 ms echo 
time, 3·2 ms repetition time, with a 192 by 192 matrix, 320–400 mm ﬁ eld of view, 
sensitivity encoding factor 1·7–2·0, and 30–50 phases per cardiac cycle.
Stress and rest perfusion
T1-weighted saturation-recovery, single-shot k-space gradient echo pulse sequence, in 
three 10-mm short axis slices, 1·0 ms echo time, 2·7 ms repetition time, 15° ﬂ ip angle, 
with a 144 by 144 matrix, 320–460 mm ﬁ eld of view (in-plane spatial resolution 
2·2–3·2 mm), sensitivity encoding factor 2, and a single saturation pre-pulse per R–R 
interval shared over three slices.
3D coronary magnetic resonance angiography
Balanced steady-state free precession pulse sequence with T2-weighted, fat saturation 
pre-pulses, 100–120 slices 0·9 mm thick, free breathing, with a respiratory navigator, 
2·3 ms echo time, 4·6 ms repetition time, with a 304 by 304 matrix, 320–460 mm ﬁ eld of 
view, sensitivity encoding factor 1·7, and duration of acquisition up to 120 ms per 
R–R interval (determined by the length of the diastolic rest period).
Late gadolinium enhancement
T1-weighted segmented inversion-recovery gradient echo pulse sequence, 10–12 short 
axis slices with one slice per breath-hold, non-selective 180° pre-pulse, echo time 1·9 ms, 
repetition time 4·9 ms, ﬂ ip angle 15°, inversion time adjusted individually according to 
the Look-Locker scan, with a 240 by 240 matrix, and a 320–460 mm ﬁ eld of view 
dependent on patient size.
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that the perfusion techniques were directly comparable.19 
Patients were imaged supine at 64 projections with 
3° intervals, every 40 s over a 180° orbit. At each projection 
eight ECG gated frames per cardiac cycle were acquired 
(64 by 64 matrix). Transaxial stress and rest slices of 
6 mm thickness (spatial resolution of about 10 mm) were 
reconstructed with a Butterworth scattered back-
projection ﬁ lter, cut-oﬀ  frequency 0·4 Nyquist, and an 
order of 6. Transaxial slices were re-orientated to the 
cardiac axes for analysis. Evidence of ischaemia was 
recorded by visual comparison of rest and stress SPECT 
perfusion scans (17-segment AHA/ACC model; a score 
of 0 [normal], 1 [equivocal], 2 [moderately reduced], 
3 [severely reduced], or 4 [absent] was assigned to each 
segment). QGS software (version 3.0) was used to 
calculate end diastolic and end systolic volumes and wall 
motion scores. As for CMR reporting and according to 
usual clinical practice,  diagnosis was made on the basis 
of all available SPECT data—ie, rest and stress perfusion, 
wall motion, and ventricular volumes.
For comparison with CMR, SPECT perfusion summed 
stress and rest scores (based on a 20-segment model: 
0=normal, 1=mildly reduced uptake, 2=moderately reduced 
uptake, 3=severely reduced uptake, and 4=absent uptake) 
were calculated with QPS software.19 All x-ray angiograms 
were done after CMR and SPECT. Clinically signiﬁ cant 
coronary heart disease was deﬁ ned as 70% or more 
stenosis of a ﬁ rst order coronary artery measuring 
2 mm or greater in diameter, or left main stem stenosis 
50% or more as measured by quantitative coronary 
angiography with use of QCAPlus software (version 
8.11.19), with a post-stenosis diameter used as the 
reference vessel diameter in cases of ostial disease.
The primary outcome was diagnostic accuracy of the 
multiparametric CMR protocol to detect clinically 
signiﬁ cant coronary heart disease deﬁ ned by x-ray 
angiography. The main secondary outcome was a 
comparison of multiparametric CMR (rest and stress 
perfusion, left ventricular function, coronary magnetic 
resonance angiography, and late gadolinium enhance-
ment) and SPECT (rest and stress perfusion, left 
ventricular function) with x-ray angiography as the 
reference. An additional analysis compared only 
the equivalent components of the CMR protocol 
with SPECT.
Statistical analysis
Statistical analyses were done by the Clinical Trials 
Research Unit, University of Leeds. The sensitivity, 
speciﬁ city, and positive and negative predictive values were 
calculated with the Wilson score method. Sensitivity and 
speciﬁ city were compared with McNemar’s test, and 
predictive values were compared with the generalised 
score statistic.26 To compare CMR and SPECT perfusion 
data for diagnostic performance with receiver operating 
characteristic analysis, a CMR summed stress score was 
calculated by adding together all segmental stress perfusion 
scores. Patients were included in the primary outcome 
analysis if they had complete data from both CMR and 
x-ray angiography and had no interim cardiovascular event. 
Diagnostic performance of CMR and SPECT were com-
pared in patients with assessable results to both tests and 
x-ray angiography. Statistical analysis was done with SAS 
software, version 9.2 at a two-sided 5% signiﬁ cance level.19
Panel 2: Criteria for a positive CMR
• Any evidence of regional wall motion abnormality (by visual analysis using the 
17-segment model23), each segment scored as 0 (normal), 1 (mild hypokinesia), 
2 (severe hypokinesia), 3 (akinesia), or 4 (dyskinesia)
• Hypoperfusion (ischaemia) assessed by visual comparison of stress and rest CMR 
perfusion scans (16 segments of the 17 segment AHA/ACC model, excluding the apical 
cap segment) with scores of 0 (normal), 1 (equivocal), 2 (subendocardial ischaemia), 
or 3 (transmural ischaemia)
• Visual severity (percentage luminal narrowing) of coronary artery stenosis in the 
coronary MR angiogram (15 coronary segments)
• Any infarct (scar) on late gadolinium-enhancement images (17 segment model) with 
scores of 0 (none), 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4 (>75%) for each segment.
If any component was positive, the overall CMR result was judged positive; if all components were negative, the CMR overall 
result was judged negative. CMR=cardiovascular magnetic resonance.
4065 patients assessed for eligibility 
3313 excluded 
1922 ineligible 
980 withheld consent
338 clinician decision
73 other
752 randomly assigned
374 assigned to SPECT then CMR†378 assigned to CMR then SPECT*
352 underwent SPECT
22 SPECT not done
349 underwent CMR
29 CMR not done
338 underwent CMR
36 CMR not done
333 underwent SPECT
45 SPECT not done
364 underwent angiography
10 angiography not done
365 underwent angiography
13 angiography not done
676 SPECT and angiography
assessable
50 SPECT unavailable
8 angiography unavailable
18 SPECT and angiography
unavailable
676 CMR and angiography
assessable
50 CMR unavailable
10 angiography unavailable
16 CMR and angiography
unavailable
628 CMR, SPECT, and
angiography assessable
Figure 2: Trial proﬁ le
*34 received SPECT before CMR. †56 received CMR before SPECT because of patient and logistic reasons. 
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A CMR result based on the components that are 
assessable by both modalities (ie, perfusion, ventricular 
function, and scar, but excluding coronary MR 
angiogram) was generated. This analysis was done to 
compare only equivalent data from both modalities and 
to assess the incremental value of CMR coronary 
imaging.
Role of the funding source
The sponsors provided ﬁ nancial support for the study 
but had no role in the study design (other than through 
its external peer review process), data collection, data 
analysis, data interpretation, or writing of the report. All 
authors had access to the primary data and have ﬁ nal 
responsibility for publication.
All randomised 
patients (N=752)
CMR and x-ray angiography 
assessable (N=676) 
CMR, SPECT, and x-ray angiography 
assessable (CMR before SPECT; N=316)
CMR, SPECT, and X-ray angiography 
assessable (SPECT before CMR; N=312)
Age (years) 60·2 (9·7) 60·3 (9·5) 60·8 (9·6) 59·9 (9·2)
Men 471 (63%) 421 (62%) 193 (61%) 200 (64%)
Body-mass index (kg/m²) 29·2 (4·4) 29·0 (4·3) 29·1 (4·4) 28·9 (4·2)
Ethnic origin
White 711 (95%) 643 (95%) 295 (93%) 302 (97%)
Black 6 (1%) 5 (1%) 1 (<1%) 3 (1%)
Asian 30 (4%) 24 (4%) 17 (5%) 6 (2%)
Other 5 (1%) 4 (1%) 3 (1%) 1 (<1%)
Smoking status
Never smoked 257 (34%) 236 (35%) 112 (35%) 112 (36%)
Ex-smoker 350 (47%) 315 (47%) 150 (47%) 144 (46%)
Current smoker 145 (19%) 125 (18%) 54 (17%) 56 (18%)
Systolic blood pressure (mm Hg) 137·9 (20·7) 138·1 (20·9) 136·9 (21·5) 138·6 (20·4)
Diastolic blood pressure (mm Hg) 79·0 (11·3) 79·0 (11·3) 78·5 (11·0) 79·2 (11·6)
Previous hospital admission for AMI or ACS 60 (8%) 54 (8%) 31 (10%) 21 (7%)
Previous PCI 38 (5%) 37 (5%) 20 (6%) 15 (5%)
Hypertension 394 (52%) 347 (51%) 160 (51%) 154 (49%)
Diabetes mellitus 96 (13%) 85 (13%) 49 (16%) 34 (11%)
Type 1 4/96 (4%) 4 (5%) 3 (6%) 1 (3%)
Type 2 92/96 (96%) 81 (95%) 46 (94%) 33 (97%)
Family history of premature heart disease
Yes 430 (57%) 392 (58%) 178 (56%) 187 (60%)
No 268 (36%) 237 (35%) 118 (37%) 99 (32%)
Unknown 54 (7%) 47 (7%) 20 (6%) 26 (8%)
Total cholesterol (mmol/L) 5·2 (1·2) 5·2 (1·2) 5·1 (1·2) 5·2 (1·2)
Simpliﬁ ed Framingham risk score* 13·7 (3·6; n=692) 13·6 (3·6; n=622) 13·7 (3·7; n=285) 13·5 (3·5; n=291)
Medication
Aspirin or clopidogrel 454 (60%) 404 (60%) 189 (60%) 184 (59%)
Statin 336 (49%) 301 (45%) 151 (48%) 129 (41%)
ACEi or A2 receptor blockers 258 (38%) 229 (34%) 112 (35%) 96 (31%)
β-blocker 235 (34%) 203 (30%) 93 (29%) 93 (30%)
Patients undergoing x-ray angiography† n=726 n=676 n=316 n=312
Any signiﬁ cant stenosis 282 (39%) 266 (39%) 125 (40%) 123 (39%)
Triple-vessel disease 45 (6%) 40 (6%) 21 (7%) 16 (5%)
Double-vessel disease 88 (12%) 83 (12%) 35 (11%) 45 (14%)
Single-vessel disease 149 (21%) 143 (21%) 69 (22%) 62 (20%)
LMS disease 23 (3%) 22 (3%) 12 (4%) 9 (3%)
LAD disease 183 (25%) 169 (25%) 79 (25%) 79 (25%)
LCX disease 133 (18%) 126 (19%) 55 (17%) 65 (21%)
RCA disease 110 (15%) 105 (16%) 51 (16%) 42 (13%)
Data are mean (SD) or n (%) unless otherwise stated. *Percentage risk of an event in the absence of chest pain over 10 years; patients with previous coronary heart disease had no risk score calculated; those older than 
age 75 years were assumed to be 75 years.27 †Numbers of patients undergoing x-ray angiography includes those with completed or partly completed non-invasive test results. AMI=acute myocardial infarction. 
ACS=acute coronary syndrome. PCI=percutaneous coronary intervention. ACEi=angiotensin converting enzyme inhibitor. A2=angiotensin 2. LMS=left main stem. LAD=left anterior descending. LCx=left circumﬂ ex. 
RCA=right coronary artery. 
Table: Baseline characteristics of patients
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Results
Figure 2 shows the trial proﬁ le. For the 338 patients 
excluded after assessment by their cardiologist, the 
pretest likelihood of coronary heart disease was so low 
that invasive investigation could not be justiﬁ ed, or 
invasive angiography was needed so urgently that there 
could be no delay for non-invasive testing. CMR was not 
done or completed in 65 (9%) patients, SPECT in 67 (9%), 
and x-ray angiography in 23 (3%). 95 patients failed to 
complete one or more tests because of claustrophobia, 
emergency hospital admission, anxiety, personal or 
domestic reasons, unrelated illness, death, technical 
reasons, and eligibility violations. Results were positive 
in 302 patients for CMR, 239 patients for SPECT, and 
282 for angiography. 384 CMR results were negative, 
419 for SPECT, and 444 for x-ray angiography. Only 
SPECT had inconclusive results (26 patients), mainly 
because of patient movement (n=12) or an attenuation 
artifact (breast, diaphragmatic, or sub-diaphragmatic). 
Four patients’ results were unavailable for analysis. The 
table shows baseline characteristics of all patients 
randomised and of those in the primary analysis; the 
demographics of all patients randomised, and especially 
of the primary analysis population, were similar. The 
overall prevalence of protocol-deﬁ ned signiﬁ cant coronary 
heart disease was 39% (table).
The median time between CMR or SPECT and x-ray 
angiography was 21 days (IQR 10–32) and 21 days (12–31), 
respectively. The median time between CMR and SPECT 
was 7 days (5–13). Ten patients had 11 serious adverse 
events, all related to x-ray angiography; eight vascular 
access site complications (haematoma), one minor neuro-
logical event, one ventricular arrhythmia, and one acute 
event needing percutaneous coronary inter vention.
For the primary outcome measure the sensitivity of 
CMR was 86·5% (95% CI 81·8–90·1), speciﬁ city 83·4% 
(79·5–86·7), positive predictive value 77·2% (72·1–81·6), 
and negative predictive value 90·5% (87·1–93·0). In the 
secondary outcome measure population, the sensitivity 
of SPECT was 66·5% (60·4–72·1), speciﬁ city 82·6% 
(78·5–86·1), positive predictive value 71·4% (65·3–76·9), 
and negative predictive value 79·1% (74·8–82·8). In this 
group the comparable values for multiparametric CMR 
were: sensitivity 86·3% (81·5–90·0), speciﬁ city 83·2% 
(79·1–86·6), positive predictive value 77·0% (71·7–81·5), 
and negative predictive value 90·3% (86·7–93·0). The 
diﬀ erences between the sensitivities and negative 
predictive values of CMR and SPECT were signiﬁ cantly 
in favour of CMR (χ² test, p<0·0001 for both), but the 
speciﬁ cities and positive predictive values were not 
(p=0·916 and p=0·061, respectively). Figure 3 shows 
example comparisons of the diﬀ erent tests.
Of the 676 patients who had assessable CMR and x-ray 
angiography, 598 (88%) had analysable coronary MR 
angiograms. From the 10 140 (15 for each of the 
676 patients) coronary artery segments theoretically 
available, 5584 (55%) were of analysable quality. When the 
coronary MR angiogram component was excluded from 
the overall CMR analysis, CMR sensitivity was 81·6% 
(76·5–85·8), speciﬁ city 85·9% (82·1–88·9), positive pre-
dic tive value 78·9% (73·7–83·3), and negative predictive 
value 87·8% (84·2–90·6). The overlap in CIs of these 
measures with those of the primary outcome analysis 
population, and the spread and heterogeneity across all 
four components, suggests that although sensitivity might 
slightly decrease, overall diagnostic accuracy does not 
diﬀ er if the coronary MR angiogram is excluded.
Compared with SPECT, the diﬀ erences between the 
sensitivities, positive predictive values, and negative 
predictive values of the CMR protocol without coronary 
MR angiography were signiﬁ cant in favour of CMR 
(p<0·0001, p=0·01, and p<0·0001, respectively), but the 
speciﬁ cities were not (p=0·224).
For the receiver operating characteristic curve analy -
sis, stress CMR (area under the curve [AUC] 0·89, 
A
B
C
AngiographySPECTCMR
Stress
Stress
Rest
Rest
Stress
Rest
Figure 3: Three examples of CMR, SPECT, and angiographic ﬁ ndings
(A) Stress perfusion CMR shows inducible hypoperfusion (ischaemia) in the septum and anterior wall (arrow shows 
dark area of hypoperfusion), SPECT is concordant (arrows show lower signal counts during stress), indicating 
anteroseptal inducible ischaemia, and angiography conﬁ rms a stenosis (arrow) in the left anterior descending 
artery. (B) Late gadolinium-enhanced CMR (arrow shows hyperenhancement in the inferior wall) and SPECT (ﬁ xed 
defect; arrows show comparable inferior defect at rest and stress) are concordant, showing a transmural inferior 
myocardial infarct with the corresponding right coronary artery chronic total occlusion (arrow) seen at 
angiography. (C) Late gadolinium-enhanced CMR shows subendocardial inferior infarction (arrow), SPECT was 
reported as normal (no wall motion abnormality), and the angiogram shows coronary atheroma but no clinically 
signiﬁ cant stenosis (or occlusion). As per study protocol, CMR in this patient was classiﬁ ed as a false positive, 
showing the potential limitations of angiography as a reference test for the detection of coronary heart disease. 
The case also shows that SPECT can miss small subendocardial infarcts. CMR=cardiovascular magnetic resonance. 
SPECT=single-photon emission computed tomography. 
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95% CI 0·86–0·91) signiﬁ cantly out-performed SPECT 
(0·74, 0·70–0·78; p<0·0001; ﬁ gure 4A). Stress perfusion 
CMR was better than SPECT even when the angiographic 
cutoﬀ  value for a clinically signiﬁ cant stenosis was 
adjusted to 50% or greater for left main stem and 50% or 
greater for left anterior descending, left circumﬂ ex artery, 
and right coronary artery (AUC for stress CMR 0·84, 
95% CI 0·81–0·87 vs AUC for SPECT 0·69, 95% CI 
0·65–0·73; p<0·0001; ﬁ gure 4B).
Stress perfusion CMR also performed better than 
SPECT when single vessel and multivessel coronary 
artery disease groups were analysed separately 
(ﬁ gure 4C, 4D, respectively). For single vessel disease the 
AUC for stress CMR was 0·87 (0·83–0·90) and for 
SPECT 0·71 (0·66–0·76; p<0·0001). For multivessel 
disease, the AUC for stress CMR was 0·91 (0·87–0·95) 
and for SPECT 0·77 (0·72–0·83; p<0·0001).
Discussion
This trial has shown that in a large population with 
suspected angina pectoris, CMR is an alternative to 
SPECT for the detection of clinically signiﬁ cant coronary 
heart disease, with better sensitivity and negative pre-
dictive values. Although CMR is already included in 
international guidelines for the non-invasive detection of 
coronary heart disease,28,29 it does not have the large scale 
diagnostic accuracy and clinical outcome data of SPECT. 
The results show that CMR oﬀ ers an accurate assess-
ment of single-vessel and multivessel coronary disease, 
irrespective of the cutoﬀ  used for severity of clinically 
signiﬁ cant angiographic stenosis (≥50% or 70%). This 
ﬁ nding is important because all non-invasive tests have 
limitations, such that alternative investigative options are 
needed. For SPECT, these limitations include the expo-
sure of patients to ionising radiation, limited spatial 
resolution, and attenuation artifacts, whereas for CMR 
they include claustrophobia, wide abdominal girth, and 
the presence of some medical implants.
The coronary heart disease prevalence in CE-MARC 
(39%) is typical of a hospital outpatient population. Only 
11% of patients had previous revascularisation or acute 
coronary syndrome. This trial population diﬀ ers substan-
tially from that of MR-IMPACT,18 a contrast dose ranging 
study in which 241 patients were enrolled after x-ray 
angiography or when scheduled for angiography after a 
positive SPECT scan. Disease prevalence in the highly 
selected MR-IMPACT population was 77%; 31% having 
had coronary angioplasty and 39% myocardial infarction. 
Furthermore, in CE-MARC all patients were prospectively 
scheduled to undergo CMR, SPECT, and x-ray angiography 
at the time of recruitment, minimising selection bias. To 
avoid confounding between the order of the tests, the order 
was randomised, and to avoid confounding between 
observers and the tests, all tests were done and interpreted 
in accordance with the strict detailed protocols.19 CMR and 
SPECT stress perfusion used identical adenosine infusion 
protocols and unlike earlier trials,18 all SPECT studies 
adopted a uniﬁ ed protocol using 99mTc tetrofosmin 
(Myoview) and cardiac gating, as advised in guidelines.24,25 
CMR and SPECT were reported using international 
criteria, by two masked independent assessors with at least 
10 years experience in their respective modality,20–22 and in a 
manner inkeeping with usual clinical practice.
Importantly, CE-MARC used a multiparametric CMR 
protocol, unlike the studies in a previous meta-analysis30 
and MR-IMPACT,18 which used only the perfusion CMR 
components. The additional clinical information provided 
by multiparametric CMR is important for individual 
patient management beyond diagnosis. Although SPECT 
provides information about ischaemia, infarction, and 
ventricular function, it provides no detail of coronary artery 
anatomy. However, omitting coronary artery imaging from 
the multiparametric CMR protocol did not impair overall 
diagnostic accuracy, and makes the investigation simpler 
and quicker. Exclusion of the coronary MR angiography 
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CMR
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All patients (angiographic cutoﬀ ≥50% LMS; 
≥70% for LAD, LCx, and RCA)
CMR 0·89 (0·86–0·91)
SPECT 0·74 (0·70–0·78)
p<0·0001
All patients (angiographic cutoﬀ ≥50% LMS, 
LAD, LCx, and RCA)
CMR 0·84 (0·81–0·87)
SPECT 0·69 (0·65–0·73)
p<0·0001
Single vessel disease (angiographic cutoﬀ ≥50% 
LMS; ≥70% for LAD, LCx, and RCA)
CMR 0·87 (0·83–0·90)
SPECT 0·71 (0·66–0·76)
p<0·0001
Two or three vessel disease (angiographic cutoﬀ 
≥50% LMS; ≥70% for LAD, LCx, and RCA)
CMR 0·91 (0·87–0·95)
SPECT 0·77 (0·72–0·83)
p<0·0001
Figure 4: Receiver operating characteristic curves of summed stress scores by population and coronary heart 
disease deﬁ nition
Generated using summed stress scores with the CMR stress perfusion component and from SPECT (n=647) for the 
whole cohort ([A] angiographic cutoﬀ  ≥50% LMS; ≥70% for LAD, LCx, and RCA; [B] angiographic cut-oﬀ  ≥50% for 
LMS, LAD, LCx, and RCA), patients with single-vessel disease (C), and patients with multivessel (two or three 
vessel) disease (D). CMR=cardiovascular magnetic resonance. SPECT=single-photon emission computed 
tomography. AUC=area under the curve. LMS=left main stem. LAD=left anterior descending. LCx=left circumﬂ ex. 
RCA=right coronary artery.
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component also made the positive predictive value of CMR 
become statistically superior to that of SPECT, because of a 
reduction in false-positive CMR results. Although there 
are no other large-scale CMR trials of similar design (MR 
IMPACT-2 has not been published), the ﬁ ndings from CE-
MARC are inkeeping with those of the recent meta-
analysis30 of 26 stress perfusion CMR studies (panel 3). 
The sensitivity of CMR in CE-MARC was similar to that in 
the CMR meta-analysis30 (86% vs 89%) and to that of a 
recent prospective study31 of 136 women (84%). However, 
direct comparisons should be made with caution (the 
meta-analysis included many small studies with hetero-
geneous populations, disease prevalence, and analysis 
methodologies).
The results of CMR compared with SPECT need to be 
considered in the context of published SPECT data, which 
are heterogeneous for population, radioisotope tracer, 
mode of stress, and protocol. Notably, before CE-MARC, 
SPECT had never been tested prospectively against 
coronary angiography in such large numbers and in a 
patient population of this kind. Previous studies of SPECT 
show a wide range in sensitivity (63–93%) and speciﬁ city 
(10–90%) compared with x-ray angiography.2–4 The 
sensitivity and speciﬁ city of SPECT in CE-MARC fell 
within the range of these other studies. A UK National 
Institute for Health and Clinical Excellence technology 
appraisal2 reported that “considerable uncertainty remains 
over the true values for sensitivity and speciﬁ city of SPECT. 
In particular, trials that assessed these values were subject 
to referral bias, in that only SPECT-positive cases were 
referred for coronary angiography, which was assumed to 
be the gold standard”. CE-MARC prospectively recruited 
patients before any imaging procedure and all patients 
had x-ray angiography, irrespective of clinical intention. 
Although this design might have increased the number of 
false negatives for both SPECT and CMR it might be more 
representative of the real sensitivity of both. The high 
speciﬁ cities reported in CE-MARC for both modalities 
might result from the use of ECG gating during SPECT 
and an awareness of dark banding artifacts during CMR 
analysis—a common source of false-positives in CMR 
perfusion studies. The results of CE-MARC and MR-
IMPACT18 are similar (AUC by ROC analysis 0·89 and 
0·86 [n=42], respectively). These concordant results using 
diﬀ erent CMR stress perfusion acquisition protocols show 
the inherent accuracy of this technique. Although we have 
not speciﬁ cally sought to address why CMR has superior 
accuracy to SPECT, it might relate partly to its higher 
spatial resolution (2·2–3·2 mm for CMR vs approximately 
10 mm in-plane for SPECT).
Our study has some limitations. Most patients were 
white northern Europeans who had not had previous 
coronary artery bypass surgery; results might diﬀ er in 
other populations. Also, CE-MARC was a single-centre 
study in which CMR and SPECT are done in high 
volumes. Extrapolation to low volume centres should be 
made with caution. Importantly, a single site and uniﬁ ed 
pharmacological stress protocol ensured consistency in 
CMR and SPECT and improved direct comparison.
CE-MARC compared two functional tests (CMR and 
SPECT)  with an anatomical test (angiography), itself an 
imperfect reference standard. Thus, false-negative results 
could occur if lesions not causing ischaemia (as assessed 
by CMR or SPECT) were judged clinically signiﬁ cant on 
the basis of angiographic stenosis severity. Quantitative 
coronary angiography, which is considered better than 
visual estimation, was used, but it is still a crude binary 
measure that fails to account for diﬀ use disease, length of 
diseased segment, serial stenoses, and microvascular 
disease. Invasive measurement of fractional ﬂ ow reserve 
is now the reference standard for the measurement of 
haemodynamic signiﬁ cance of a coronary artery stenosis 
and should be used in future studies. Indeed, results 
from the FAME trial32 showed a wide discrepancy between 
angiographic stenosis classiﬁ cation and fractional ﬂ ow 
re serve measurements. 
CE-MARC is the largest, prospective, real world assess-
ment of CMR. The ﬁ ndings of CE-MARC support the 
wider adoption of CMR for the diagnosis and manage ment 
of stable coron ary heart disease patients, in view of the 
growing concern of the cancer risk associated with medical-
source ionising radiation.
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Panel 3: Research in context
Systematic review
We searched PubMed for original papers in English, with no date restriction, with the terms 
“cardiovascular magnetic resonance”, “stress perfusion imaging”, “coronary heart disease”, 
“ischaemic heart disease”, and “single photon emission computed tomography”. There are 
no large scale diagnostic accuracy studies of a multiparametric cardiovascular magnetic 
resonance (CMR) protocol for the detection of coronary heart disease.  A meta-analysis30 
has shown that stress perfusion CMR is highly sensitive but only moderately speciﬁ c for 
the detection of coronary heart disease. A small subgroup analysis of the MR-IMPACT trial18 
suggests that stress perfusion CMR and single-photon emission computed tomography 
(SPECT) have much the same diagnostic accuracy.
Interpretation
CE-MARC is the ﬁ rst large-scale trial of a multiparametric CMR protocol for the diagnosis 
of stable coronary heart disease. CMR had better sensitivity and negative predictive values 
than SPECT for coronary heart disease diagnosis, with much the same speciﬁ city. These 
ﬁ ndings support the wider adoption of CMR for coronary heart disease diagnosis and its 
inclusion in evidence-based clinical management guidelines.
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